Everyday Freedom™for Veterans

A breakthrough treatment for anxiety attacks and PTSD symptoms

Freespira is the only FDA-cleared combination treatment (durable medical equipment plus digital therapeutics) proven to reduce or eliminate panic attacks and post-traumatic stress disorder (PTSD) symptoms. Unlike medication or talk therapy, in 28 days Freespira addresses the underlying breathing irregularities for individuals suffering from these debilitating anxiety conditions. Freespira treatment is available to veterans with VA benefits.

Typical traumatic stress or panic disorder symptoms may include:

CHEST PAINS

SHORTNESS OF BREATH

UNCOMFORTABLE FLASHBACKS

symptoms_right
Since completing Freespira, I am able to control my anger, and I am not as depressed anymore. I’ve learned to cope better and am functioning well. I enjoy family activities again, and my family enjoys being around me, too. Freespira gave me an outlet to control my symptoms so I am able to function in everyday life.
— Gary, Sergeant First Class, United States Army, Retired
[Freespira] made me more calm, reduced anxious feelings after each session and eased symptoms of PTSD. It is a wonderful non-medication treatment that brings lasting results.
— Specialist, United States Army, Retired

Freespira is an at-home treatment option for PTSD and panic disorder, making access to help easier and more convenient for patients in both urban and rural locations.

Make a Referral

Freespira helps deliver long-term benefits

Panic attacks and PTSD lead to significantly higher average additional claims spend per patient:

PANIC DISORDER
$5,3251
PTSD
$13,9812
13.6%
Combined, comorbid prevalence of panic disorder and ptsd adults and teens3

Panic attacks accompany a range of other health conditions. The 28.3% lifetime prevalence of panic attacks means many people experience a panic attack without meeting the full diagnostic criteria for panic disorder.4

98%

Panic disorder patients have at least one behavioral health comorbidity; among the most common, major depressive disorder, anxiety disorder, and alcohol use disorders5

avrage_icon
Freespira is easy to use, with 77% average adherence to the twice-a-day treatment over the 28-day protocol among participants in a study by VA researchers. (Ostacher et al., 2021)
home_icon
Freespira is shipped directly to the patient’s home and includes carrying case and paid return shipping after treatment is complete.
fda_icon
Freespira is the only FDA-cleared, medication-free digital therapeutic treatment proven to reduce or eliminate PTSD symptoms and panic attacks.
Freespira coaches provide one-on-one training and tech support on how to use the system.

Freespira Solution Graphic%

Relief for veterans at the ready

Freespira can be used with talk therapy and medication.

After authorization, veterans will receive the Freespira system, which includes a sensor, a small breath-sampling tube (cannula), and a tablet with an app.

Dedicated coaches virtually guide patients through treatment sessions.*

The treatment corrects irregular breathing patterns—underlying physiologic factors with PTSD and repeated anxiety attacks—and trains the body to reduce or eliminate them.


Freespira is listed on the Federal Supply Schedule 65lla – 36F79720D0158, through our SDVOSB partner, Franklin Young International, Inc.

accessible_img

Help veterans stop anxiety attacks. Make a referral today or download consult instructions.

MAKE A REFERRAL

*Freespira coaches are licensed clinicians, but they do not provide clinical diagnoses, clinical assessments, or clinical guidance to veterans. They are available to answer questions and help veterans undergoing Freespira treatment use the system and promote protocol adherence.

1 See Konnopka, et al., https://pubmed.ncbi.nlm.nih.gov/31646432/
2 See National Academies, https://pubmed.ncbi.nlm.nih.gov/25077185/
3 See National Institutes of Health, https://www.nimh.nih.gov/health/statistics/panic-disorder
4 See Kessler, et al., https://pubmed.ncbi.nlm.nih.gov/16585471/
5 See Virpi, et al., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3520420/
6 See Kaplan, et al., https://doi.org/10.1007/s10484-020-09465-0
7 See Ostacher, et al., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8553693/
8 See Tolin, et al., https://pubmed.ncbi.nlm.nih.gov/28194546/